Prostate-specific membrane antigen PSM (35-40), human

INCSGK-acid

  • Description

  • Application Data

Description

Prostate-specific membrane (PSM) antigen is a high tumour-grade prostate cancer biomarker.

See full description

Application Data

Catalogue number crb1001234
Molecular Weight 620.3
Sequence (one letter code)

INCSGK-acid

Sequence (three letter code)

H-Ile-Asn-Cys-Ser-Gly-Lys-OH

Purity >95%
Storage -20°C
References

Chang, (2004). Overview of prostate-specific membrane antigen. Nat. Rev. Urol.,  6(10): S13. PMID: 16985927.

Morgenroth et al., (2019). Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer. Breast Cancer Res., 21: 116. doi: 10.1186/s13058-019-1205-1.

Manufactured in: United Kingdom
Data Sheet Material Safety Data Sheet (MSDS)

Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein found in all prostate tissue; androgen levels negatively regulate its expression. PSMA expression correlates with cancer aggressiveness and represents an independent indicator of poor disease outcomes. PSMA is being explored as a clinical biomarker to allow differentiation of aggressive prostate cancers from other cases using imaging and RT-PCR.

The epitope PSMA (35-40) is from the splice isoform PSMA-1. There has been progress in generating PSMA targeting radioligands as a therapy for various cancers. Α and β radiation probes such as 177Lu-PSMA-617 have been developed and shown in trials to be clinically effective treatments against metastatic prostate cancer. Other studies have tested the PSMA targeting radioligands efficacy against triple-negative breast cancer cells. Further work with the PSMA (35-40) epitope could help progress the outlook for these aggressive cancers.

Prostate-specific membrane antigen PSM (35-40), human

Cat No.Pack SizePriceQty.
0.5mg£85.00
1mg£110.00
Bulk Quote